MIRA Pharmaceuticals (NASDAQ:MIRA) | WebDisclosure

Basculer en Français

8295	Companies
114863	Keywords
55304	Articles
62446	Press releases

Home
Companies
MIRA Pharmaceuticals

BRIEF

published on 09/27/2024 at 13:35, 1 month 23 days ago

MIRA Pharmaceuticals Reveals New Data on Ketamir-2 at Annual Pain Therapeutics Summit

Preclinical Data MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain Pain Therapeutics Summit
PRESS RELEASE

published on 09/27/2024 at 13:30, 1 month 23 days ago

MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024
MIRA Pharmaceuticals presents preclinical results at Pain Therapeutics Summit showcasing that Ketamir-2 achieves 100% reversal of neuropathic pain. The innovative therapy targets NMDA receptors for enhanced efficacy

Preclinical Results MIRA Pharmaceuticals Ketamir-2 NMDA Receptor Neuropathic Pain
BRIEF

published on 09/18/2024 at 13:05, 2 months 3 days ago

MIRA Pharmaceuticals poursuit le développement du kétamir-2, en visant une efficacité clinique précoce en 2025

Essai De Phase I Ketamir-2 Douleur Neuropathique MIRA Pharmaceutique La FDA
BRIEF

published on 09/18/2024 at 13:05, 2 months 3 days ago

MIRA Pharmaceuticals Pushes Forward with Ketamir-2 Development, Targeting Early Clinical Efficacy in 2025

FDA Phase I Trial MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain
PRESS RELEASE

published on 09/18/2024 at 13:00, 2 months 3 days ago

MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025
MIRA Pharmaceuticals announces progress in clinical development planning for novel oral ketamine analog, emphasizing early efficacy signal detection in humans by 2025. IND filing on schedule for December 2024 with focus on neuropathic pain treatment

Clinical Development MIRA Pharmaceuticals Ketamine Analog Neuropathic Pain Clinical Efficacy
BRIEF

published on 09/11/2024 at 13:35, 2 months 9 days ago

MIRA Pharmaceuticals Targets Neuropathic Pain with Ketamir-2, Submits Pre-IND Request to FDA

Preclinical Study Pharmaceutical Development FDA Submission Ketamir-2 Neuropathic Pain
BRIEF

published on 09/11/2024 at 13:35, 2 months 9 days ago

MIRA Pharmaceuticals cible la douleur neuropathique avec le kétamir-2 et soumet une demande de pré-IND à la FDA

Développement Pharmaceutique Soumission À La FDA Étude Préclinique Ketamir-2 Douleur Neuropathique
PRESS RELEASE

published on 09/11/2024 at 13:30, 2 months 9 days ago

MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA
MIRA Pharmaceuticals, Inc. selects neuropathic pain as the primary indication for its novel oral ketamine analog, Ketamir-2, targeting neurologic disorders. Pre-IND meeting with FDA anticipated in Nov 2024

Preclinical Studies MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain FDA Meeting
BRIEF

published on 08/26/2024 at 14:05, 2 months 25 days ago

MIRA Pharmaceuticals parvient à inverser à 100 % la douleur neuropathique grâce au kétamir-2 oral dans le cadre d'une étude révolutionnaire

Efficacité Étude Clinique Ketamir-2 Douleur Neuropathique MIRA Pharmaceutique
BRIEF

published on 08/26/2024 at 14:05, 2 months 25 days ago

MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain With Oral Ketamir-2 in Breakthrough Study

Clinical Study Efficacy MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain

Accesswire

Published on 11/21/2024 at 12:00, 1 hour 5 minutes ago

Alset AI Announces Full Repayment of $3.7 Million Secured Loan with Interest from Portfolio Company, Significantly Strengthening Balance Sheet
Published on 11/21/2024 at 12:00, 1 hour 5 minutes ago

Battery X Metals Commences Strategic Initiatives to Strengthen Balance Sheet
Published on 11/21/2024 at 11:30, 1 hour 35 minutes ago

FireFox Trenching Returns More High-Grade Gold at the Mustajärvi Gold Project in Lapland, Finland
Published on 11/21/2024 at 10:03, 3 hours 2 minutes ago

Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 3 hours 5 minutes ago

BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 12:35, 30 minutes ago

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 50 minutes ago

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 12:06, 59 minutes ago

IVU AG publishes Quarterly Report Q3-2024
Published on 11/21/2024 at 12:00, 1 hour 5 minutes ago

Holding(s) in Company
Published on 11/21/2024 at 11:30, 1 hour 35 minutes ago

APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived

Les Echos

Published on 11/21/2024 at 06:58, 6 hours 7 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 6 hours 7 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 6 hours 7 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 16 hours 58 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 17 hours 45 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE